Karin Innes
FB Rice
Articles
Can two vials unite to create a patent term extension right?
Australia - May 15 2020 In 2016 the Productivity Commission’s “Intellectual Property Arrangements - Inquiry Report” recommended to the Australian Federal Government that…
The Australian 25 Year Patent
Australia - September 18 2019 Since 1998, Australia has had an extension of patent term (EoT) regime that allows for an extension of term of up to 5 years for pharmaceutical…
The challenge in obtaining broad antibody genus claims in the US
USA - May 29 2018 Functionally defined genus claims are vulnerable to invalidity based on lack of written description support, particularly where it is difficult to…
Interfering RNA (iRNA) is no interference to manner of manufacture in Australia
Australia - October 18 2016 Following the Australian High Court decision in Myriad, isolated nucleic acid was found not to constitute patent eligible subject matter. The High…
Sale of a drug under confidentiality is not considered invalidating secret use under US post AIA
Australia, USA - March 16 2016 For US patent applications filed post introduction of the America Invents Act (AIA) (which changed from first-to-invent to first-to-file), sale and…
